Literature DB >> 2303077

Dangerous effects of tin-protoporphyrin plus photoirradiation on neonatal rats.

H Keino1, H Nagae, S Mimura, K Watanabe, S Kashiwamata.   

Abstract

In vivo and in vitro effects of porphyrins (tin-protoporphyrin [SnPP], cobalt-mesoporphyrin, haemin and protoporphyrin) on neonatal rats were investigated. Under photoirradiation a high mortality rate was recognized in SnPP injected rats. None died from the application of SnPP without photoirradiation. In photoirradiated rats the median lethal dose (LD50) value of SnPP was calculated to be about 7.4 mumol/kg body weight. Haemolysis and malonaldehyde formation of red blood cells were induced by SnPP together with photoirradiation. SnPP may be useful in reducing bilirubin levels in severely jaundiced infants under non-photoirradiated conditions or dim light, but prophylactic administration of SnPP to the majority of infants is not recommended.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303077     DOI: 10.1007/bf02106294

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

Review 1.  Purple versus yellow: preventing neonatal jaundice with tin-porphyrins.

Authors:  A F McDonagh
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

2.  Sn-protoporphyrin lowers serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and potently inhibits hepatic heme oxygenase activity in normal human subjects.

Authors:  L Berglund; B Angelin; R Blomstrand; G Drummond; A Kappas
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

3.  Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility.

Authors:  A Kappas; G S Drummond; T Manola; S Petmezaki; T Valaes
Journal:  Pediatrics       Date:  1988-04       Impact factor: 7.124

4.  Sn-protoporphyrin: a consideration of the first clinical trial in human neonates.

Authors:  D K Stevenson; H J Vreman
Journal:  Pediatrics       Date:  1988-06       Impact factor: 7.124

5.  Chemoprevention of neonatal jaundice: potency of tin-protoporphyrin in an animal model.

Authors:  G S Drummond; A Kappas
Journal:  Science       Date:  1982-09-24       Impact factor: 47.728

6.  Antioxidant activity of albumin-bound bilirubin.

Authors:  R Stocker; A N Glazer; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Pharmacological and biological effects of tin-protoporphyrin on neonatal hyperbilirubinemic Gunn rats.

Authors:  H Nagae; H Keino; K Watanabe; S Kashiwamata
Journal:  Pediatr Res       Date:  1988-08       Impact factor: 3.756

8.  Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation.

Authors:  G S Drummond; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

  9 in total
  8 in total

1.  Selectivity of imidazole-dioxolane compounds for in vitro inhibition of microsomal haem oxygenase isoforms.

Authors:  Robert T Kinobe; Jason Z Vlahakis; Hendrik J Vreman; David K Stevenson; James F Brien; Walter A Szarek; Kanji Nakatsu
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 2.  Metalloporphyrins in the management of neonatal hyperbilirubinemia.

Authors:  David K Stevenson; Ronald J Wong
Journal:  Semin Fetal Neonatal Med       Date:  2009-12-16       Impact factor: 3.926

3.  Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia.

Authors:  V K Bhutani; R Poland; L D Meloy; T Hegyi; A A Fanaroff; M J Maisels
Journal:  J Perinatol       Date:  2016-03-03       Impact factor: 2.521

4.  Antimycobacterial effect of IFNG (interferon gamma)-induced autophagy depends on HMOX1 (heme oxygenase 1)-mediated increase in intracellular calcium levels and modulation of PPP3/calcineurin-TFEB (transcription factor EB) axis.

Authors:  Nisha Singh; Pallavi Kansal; Zeeshan Ahmad; Navin Baid; Hariom Kushwaha; Neeraj Khatri; Ashwani Kumar
Journal:  Autophagy       Date:  2018-05-10       Impact factor: 16.016

Review 5.  Ethnopharmacological Approaches for Therapy of Jaundice: Part I.

Authors:  Devesh Tewari; Andrei Mocan; Emil D Parvanov; Archana N Sah; Seyed M Nabavi; Lukasz Huminiecki; Zheng Feei Ma; Yeong Yeh Lee; Jarosław O Horbańczuk; Atanas G Atanasov
Journal:  Front Pharmacol       Date:  2017-08-15       Impact factor: 5.810

Review 6.  Heme Oxygenase-1 as a Pharmacological Target for Host-Directed Therapy to Limit Tuberculosis Associated Immunopathology.

Authors:  Krishna C Chinta; Hayden T Pacl; Anupam Agarwal; Adrie J C Steyn
Journal:  Antioxidants (Basel)       Date:  2021-01-26

Review 7.  Efficacy and Safety Concerns with Sn-Mesoporphyrin as an Adjunct Therapy in Neonatal Hyperbilirubinemia: A Literature Review.

Authors:  Prakar Poudel; Sudhir Adhikari
Journal:  Int J Pediatr       Date:  2022-07-18

8.  Autoantibody-Mediated Erythrophagocytosis Increases Tuberculosis Susceptibility in HIV Patients.

Authors:  Youchao Dai; Yi Cai; Xin Wang; Jialou Zhu; Xiaoqing Liu; Houming Liu; Linghua Li; Yinze Zhang; Shengze Liu; Zhihua Wen; Carl G Feng; Xinchun Chen; Xiaoping Tang
Journal:  mBio       Date:  2020-02-25       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.